Immunotherapy. 2013;5(9):923-925. Rather than focusing on the blockade of IL-17A or IL-17F alone, Wedebye Schmidt et al. examined the effects of blockade of both IL-17A and IL-17F. They report that ...
Adam Hayes, Ph.D., CFA, is a financial writer with 15+ years Wall Street experience as a derivatives trader. Besides his extensive derivative trading expertise, Adam is an expert in economics and ...
Peptidream Inc. has announced progression of an oral dual IL-17A and IL-17F macrocyclic peptide inhibitor for psoriasis, with the program entering the company’s clinical development portfolio.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results